LungArchives
Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
Lung 1 min.
The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. The study sought...
Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients
Lung 6 min.
The emergence of actionable biomarkers and targeted therapy changed the treatment paradigm in advanced non-small cell lung cancer (NSCLC) [1, 2]. Epidermal growth factor receptor (EGFR) is present in about a third of all patients with advanced non-squamous NSCLC, with higher prevalence in Asians, non-smokers,...
Comparison of segmentectomy and lobectomy for non-small cell lung cancer with visceral pleural invasion
Lung 4 min.
Surgical resection is currently the mainstay of curative treatment for early-stage non-small cell lung cancer (NSCLC). Visceral pleural invasion (VPI) has a significant impact on staging and prognosis and is an important factor in determining surgical strategy [1, 2]. Previous studies demonstrated that...
Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer
Lung 3 min.
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small-cell lung cancer (NSCLC) [1, 2]. Among them, atezolizumab demonstrated superior efficacy and safety in the Phase III OAK trial, showing a significant improvement in overall survival (OS) compared with...
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer
Lung 1 min.
Although immune checkpoint inhibitors (ICIs) form the cornerstone of first-line treatment for non-small cell lung cancer (NSCLC), the challenge remains to improve patients' long-term outcomes. Eftilagimod alfa (efti) activates antigen-presenting cells, triggering T cell activation and a sustained immune...
